Please login to the form below

risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well

Latest news

Cosentyx, Entresto drive topline growth for Novartis in Q4

However, in head-to-head trials with both AbbVie’s Humira (adalimumab) and Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi (risankizumab) against Novartis’ blockbuster IL-17 inhibitor Cosentyx (secukinumab) – which has sales currently running at around $1bn a quarter – and
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis.
J&J splashes $750m on anti-inflammatory drug bermekimab

secukinumab) and AbbVie’s Skyrizi (risankizumab).
Novartis’ Cosentyx misses the mark in Humira head-to-head

This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Sales are projected at $1.93bn for 2013. Skyrizi (risankizumab) treats psoriasis.
Drug launches to watch in 2019

It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Director – UK Office: Excellent salary and benefits

Account Director, Medical Education: Salary TBC

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Experienced medical editor: Competitive salary and bonus scheme

Senior Account Manager: Salary TBC

Account Director, Healthcare Communications: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior External Communications Lead: £Competitive Salary

Account Manager (PR): Great Benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer: Salary TBC

Account Director: £Competitive Salary

Account Manager: £Competitive Salary

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Publications director: Competitive salary and bonus scheme

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Senior Medical Writer, MedComms Agency: Salary TBC

PMHub

Add my company

Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

The role of women in science and technology: Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances: China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program: Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....